Bambusa Therapeutics (BBTX) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bambusa Therapeutics is the larger company by market cap ($815.1 million vs $697.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBTX | SLDB |
|---|---|---|
| Share price | $16.00 | $6.25 |
| Market cap | $815.08M | $697.57M |
| 1-day change | +2.89% | -2.95% |
| YTD return | — | +10.82% |
| 1-year return | — | +32.98% |
| 5-year return | — | -77.78% |
| EPS (TTM) | $-1.73 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-174.32M |
| 52-week high | $17.65 | $11.45 |
| 52-week low | $13.60 | $4.65 |
| Distance from 52-week high | -9.35% | -45.41% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +199.36% |
| Average volume | 359.41K | 1.30M |
| Shares outstanding | 50.94M | 111.61M |
| Employees | 26 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bambusa Therapeutics
BBTX stock →Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
BBTX vs SLDB FAQ
Which is bigger, Bambusa Therapeutics or Solid Biosciences?
Bambusa Therapeutics (BBTX) is larger, with a market capitalization of $815.08M compared with $697.57M for Solid Biosciences (SLDB).
Are Bambusa Therapeutics and Solid Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.